1.Healthy Japanese male and female adult subjects aged >= 20 years of age at the time of signing of informed consent.2.Participant who completed 2 doses primary vaccinations with another specified mRNA vaccine (SARS-CoV-2) which is available in Japan 6 to 12 months prior to the trial vaccination.

1.Healthy Japanese male and female adult subjects aged >= 20 years of age at the time of signing of informed consent.2.Participant who completed 2 doses primary vaccinations with another specified mRNA vaccine (SARS-CoV-2) which is available in Japan 6 to 12 months prior to the trial vaccination.